2.72
4.21%
0.11
Pre-mercato:
3.28
0.56
+20.59%
Precedente Chiudi:
$2.61
Aprire:
$2.648
Volume 24 ore:
434.90K
Relative Volume:
0.24
Capitalizzazione di mercato:
$101.79M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.45%
1M Prestazione:
-32.84%
6M Prestazione:
-42.86%
1 anno Prestazione:
+0.00%
Metagenomi Inc Stock (MGX) Company Profile
Nome
Metagenomi Inc
Settore
Industria
Telefono
(510) 871-4880
Indirizzo
5959 HORTON STREET, EMERYVILLE
Confronta MGX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
2.72 | 101.79M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-05-07 | Iniziato | H.C. Wainwright | Buy |
2024-05-02 | Downgrade | JP Morgan | Overweight → Neutral |
2024-03-05 | Iniziato | BMO Capital Markets | Outperform |
2024-03-05 | Iniziato | Chardan Capital Markets | Buy |
2024-03-05 | Iniziato | JP Morgan | Overweight |
2024-03-05 | Iniziato | Jefferies | Buy |
2024-03-05 | Iniziato | TD Cowen | Outperform |
2024-03-05 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Metagenomi Inc Borsa (MGX) Ultime notizie
Metagenomi aiming for clinical trials of gene-editing therapy in 2026 - Hemophilia News Today
Metagenomi outlines anticipated 2025 milestones - MSN
Metagenomi advances gene editing therapies into 2025 - Investing.com
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - GlobeNewswire
Metagenomi Reports 16-Month Breakthrough in Hemophilia A Treatment Development Program - StockTitan
Metagenomi Announces New Appointment to its Board of Directors - GlobeNewswire
Metagenomi, Inc. Announces Appointment of Eric Bjerkholt to Its Board of Directors, Serving on Audit and Compensation Committees, Effective January 27, 2025 - Marketscreener.com
Metagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutions - Yahoo Finance
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully - Simply Wall St
Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) - MSN
Geode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Metagenomi CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Metagenomi: Q3 Earnings Snapshot - Marketscreener.com
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Up 445.1% in December - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Verition Fund Management LLC Makes New Investment in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - The Eastern Progress Online
MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options - The Eastern Progress Online
2 ‘Monster’ Stocks to Snap Up Before 2025 - MSN
Metagenomi (NASDAQ:MGX) Price Target Raised to $14.00 - Defense World
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Eastern Progress Online
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference 'RNA at the Bench and Bedside IV” - The Manila Times
Metagenomi Presents Highly Specific and Efficient Genome - GlobeNewswire
Metagenomi, Inc. Presents Highly Specific and Efficient Genome Editing Tools At Nature Conference RNA At the Bench and Bedside IV - Marketscreener.com
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts - Benzinga
Metagenomi (NASDAQ:MGX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Metagenomi presents updated preclinical NHP data at ASH meeting - TipRanks
Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry - Simply Wall St
Metagenomi presents updated preclinical data in Hemophilia A at ASH - TipRanks
Metagenomi's Gene Therapy Shows Breakthrough 16-Month Durability in Hemophilia A Preclinical Data - StockTitan
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting - Yahoo Finance
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th - EIN News
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit - The Eastern Progress Online
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
Lawsuit Deadline Notice: Metagenomi, Inc. Investors who lost over $100,000 with NASDAQ: MGX shares should contact the Shareholders Foundation - The Eastern Progress Online
Metagenomi Inc Azioni (MGX) Dati Finanziari
Non sono disponibili dati finanziari per Metagenomi Inc (MGX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):